Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Authors
Keywords
-
Journal
CLINICAL DRUG INVESTIGATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-31
DOI
10.1007/s40261-019-00863-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
- (2017) A. J. Kivitz et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Rheumatoid arthritis
- (2016) Josef S Smolen et al. LANCET
- Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis
- (2016) Y H Lee et al. LUPUS
- Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
- (2016) Geoffrey A Smith et al. Nature Chemical Biology
- Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Selective JAK inhibitors in development for rheumatoid arthritis
- (2014) Peter Norman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Network meta-analysis for comparing treatment effects of multiple interventions: an introduction
- (2014) Ferrán Catalá-López et al. RHEUMATOLOGY INTERNATIONAL
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
- (2013) Satoshi Kubo et al. ANNALS OF THE RHEUMATIC DISEASES
- Evidence Synthesis for Decision Making 4
- (2013) Sofia Dias et al. MEDICAL DECISION MAKING
- Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
- (2012) J. P. T. Higgins et al. Research Synthesis Methods
- Automating network meta-analysis
- (2012) Gert van Valkenhoef et al. Research Synthesis Methods
- Pathogenetic factors underlying juvenile deep vein thrombosis (DVT) in Indians
- (2010) Renu Saxena et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
- (2010) Georgia Salanti et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
- (2008) D. Aletaha et al. ARTHRITIS AND RHEUMATISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now